VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viridian Therapeutics, Inc.\DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$20.80+1.77 (+9.30%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Viridian Therapeutics, Inc.\DE revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 21 | Q3 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $233.00K | $6.00K | $0 | $70.00M | $0 | $0 | $0 | $0 | – | – | – | – | 82.0% | – |
| Collaboration | $51.00K | $135.00K | $132.00K | $570.00K | $75.00K | $72.00K | $72.00K | $86.00K | – | – | – | – | 18.0% | -32.0% |
| Collaboration Revenue | – | – | – | – | – | – | – | – | – | – | $214.00K | $208.00K | – | – |
| Grant revenue | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Viridian Therapeutics, Inc.\DE's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.